Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722538 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
A Phase 1 study, sponsored by Taris Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02722538: Completed Phase 1 study, sponsored by Taris Biomedical.
NCT02722538 is a Phase 1 study that has completed, run by Taris Biomedical. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02722538, a Phase 1 study, has completed, sponsored by Taris Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).
Interventions
- DRUG Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 1 |
What the finished NCT02722538 record still lists
NCT02722538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is the first listed.
NCT02722538 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02722538 about?
NCT02722538 is a clinical study titled "Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer". The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).
What is the current status of trial NCT02722538?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-05-31. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02722538?
The interventions under investigation include: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 (DRUG).
Who is sponsoring clinical trial NCT02722538?
This trial is sponsored by Taris Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02722538's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI